FluMist Quadrivalent is the first influenza vaccine to contain four strains of the influenza virus, two influenza A strains and two influenza B strains. Like the already approved FluMist trivalent, the quadrivalent vaccine contains weakened forms of the virus strains and is administered as a spray into the nose.
The safety and effectiveness of FluMist Quadrivalent is supported by studies conducted previously for the FluMist trivalent formulation and three new clinical studies involving approximately 4,000 children and adults. The studies demonstrated that the immune responses were similar between FluMist Quadrivalent and FluMist.
Adverse reactions reported were similar among those receiving FluMist Quadrivalent and FluMist. The most commonly reported adverse reactions were runny or stuffy nose in both children and adults and headache and sore throat in adults. FluMist Quadrivalent is manufactured by MedImmune in Gaithersburg, Md.
Related Articles on Flu Vaccination:
New Jersey Law Would Mandate Healthcare Worker Vaccinations
Nurses Union Criticizes Recommendation to Make Vaccination Requirement of Employment
Oregon Senate Committee Works on Healthcare Worker Vaccination Bill
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
